VivoSense

Develops digital endpoints from wearable devices

Newport Beach, California, United States

About VivoSense

VivoSense develops digital endpoints from wearable devices to enhance clinical trials. By capturing and processing data from these devices, VivoSense transforms raw sensor information into reliable digital endpoints that provide precise insights into patient health and treatment outcomes. The company serves pharmaceutical companies, biotech firms, and research institutions, offering a comprehensive suite of services that includes data design, collection, cleaning, analysis, and reporting. This end-to-end approach allows clients to gain actionable insights, leading to more effective treatments. VivoSense differentiates itself by focusing on the integration of wearable technology and advanced data analytics, aiming to improve the accuracy and efficiency of clinical trials. The goal is to optimize clinical trials and ultimately enhance patient outcomes.

Newport Beach, CaliforniaHeadquarters
2010Year Founded
$26.3MTotal Funding
SERIES_ACompany Stage
Data & Analytics, Biotechnology, HealthcareIndustries
11-50Employees

Risks

Emerging startups in digital health could threaten VivoSense's market share.
Rapid tech advancements may strain VivoSense's resources to update software and analytics.
Data privacy concerns could impose additional compliance costs for VivoSense.

Differentiation

VivoSense specializes in digital endpoints from wearable devices for clinical trials.
The company offers end-to-end services from data collection to analysis and reporting.
VivoSense focuses on precision insights, enhancing clinical trial accuracy and reliability.

Upsides

Increased adoption of decentralized trials boosts demand for VivoSense's wearable technology.
The global wearable medical device market is projected to grow significantly by 2030.
FDA acceptance of digital health technologies opens regulatory pathways for VivoSense.

Funding

Total raised$26.26 M
Latest valuation$125.00 M
StageSERIES_A
$25
$125.00 M
EARLY VC
4/30/2019
$2
$10.00 M